VYNE Therapeutics (VYNE) Competitors $0.41 -0.02 (-3.98%) Closing price 04:00 PM EasternExtended Trading$0.41 0.00 (-1.19%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. TENX, AKTX, MAAQ, SCYX, SONN, ITRM, IMA, KLTO, DARE, and ALVRShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Tenax Therapeutics (TENX), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), SCYNEXIS (SCYX), Sonnet BioTherapeutics (SONN), Iterum Therapeutics (ITRM), ImageneBio (IMA), Klotho Neurosciences (KLTO), Dare Bioscience (DARE), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Its Competitors Tenax Therapeutics Akari Therapeutics Mana Capital Acquisition SCYNEXIS Sonnet BioTherapeutics Iterum Therapeutics ImageneBio Klotho Neurosciences Dare Bioscience AlloVir VYNE Therapeutics (NASDAQ:VYNE) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of VYNE or TENX? 83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 4.8% of VYNE Therapeutics shares are held by insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate VYNE or TENX? VYNE Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 1,413.68%. Tenax Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 131.66%. Given VYNE Therapeutics' higher possible upside, equities research analysts plainly believe VYNE Therapeutics is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has higher earnings & valuation, VYNE or TENX? Tenax Therapeutics has lower revenue, but higher earnings than VYNE Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$500K21.03-$39.83M-$0.90-0.46Tenax TherapeuticsN/AN/A-$17.60M-$0.92-8.45 Is VYNE or TENX more profitable? Tenax Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -8,097.69%. Tenax Therapeutics' return on equity of -31.34% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-8,097.69% -77.57% -63.09% Tenax Therapeutics N/A -31.34%-30.39% Which has more risk & volatility, VYNE or TENX? VYNE Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Does the media prefer VYNE or TENX? In the previous week, VYNE Therapeutics had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for VYNE Therapeutics and 0 mentions for Tenax Therapeutics. VYNE Therapeutics' average media sentiment score of 0.00 equaled Tenax Therapeutics'average media sentiment score. Company Overall Sentiment VYNE Therapeutics Neutral Tenax Therapeutics Neutral SummaryVYNE Therapeutics beats Tenax Therapeutics on 8 of the 15 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.52M$2.64B$9.05B$10.60BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-0.4623.7285.8527.35Price / Sales21.03578.53535.75201.60Price / CashN/A173.2337.9261.55Price / Book0.125.6313.056.78Net Income-$39.83M$32.78M$3.30B$275.79M7 Day Performance27.79%6.23%4.79%2.63%1 Month Performance43.87%13.69%9.97%9.12%1 Year Performance-77.68%2.69%85.15%35.86% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.5681 of 5 stars$0.41-4.0%$6.25+1,413.7%-76.4%$10.52M$500K-0.4630Analyst ForecastHigh Trading VolumeTENXTenax Therapeutics1.9908 of 5 stars$7.41+1.6%$18.00+143.1%+140.9%$33.79MN/A-8.059AKTXAkari Therapeutics2.7229 of 5 stars$1.02-0.1%$3.30+223.5%-66.2%$33.27MN/A0.009Analyst ForecastGap DownMAAQMana Capital AcquisitionN/A$4.07+0.2%N/A+1,886.4%$33.07MN/A0.001Gap UpSCYXSCYNEXIS0.477 of 5 stars$0.78-26.0%N/A-47.9%$32.58M$3.26M-1.9460High Trading VolumeSONNSonnet BioTherapeutics1.7363 of 5 stars$4.74-3.0%$20.00+321.6%+5.1%$32.40M$20K0.0010News CoverageAnalyst ForecastGap DownITRMIterum Therapeutics1.485 of 5 stars$0.68-0.3%$9.00+1,217.7%-20.2%$32.22MN/A-0.8010Analyst ForecastIMAImageneBio2.892 of 5 stars$7.85+1.9%$35.50+352.2%-59.5%$31.48M$9.16M-1.0270Negative NewsShort Interest ↑KLTOKlotho Neurosciences0.6606 of 5 stars$0.50-1.2%N/AN/A$30.69MN/A-1.11N/AAnalyst ForecastGap DownDAREDare Bioscience1.922 of 5 stars$2.13+1.7%$10.00+370.6%-29.8%$28.65M$10K-0.9930Positive NewsAnalyst ForecastALVRAlloVirN/A$5.61+17.6%N/A-57.7%$28.29MN/A-0.28110High Trading Volume Related Companies and Tools Related Companies TENX Competitors AKTX Competitors MAAQ Competitors SCYX Competitors SONN Competitors ITRM Competitors IMA Competitors KLTO Competitors DARE Competitors ALVR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
